Mechanism of action of mitoxantrone.


Mitoxantrone, a synthetic anthracenedione, was developed in the 1980s as a doxorubicin analogue in a program to find a cytotoxic agent with decreased cardiotoxicity compared with doxorubicin. It was approved by the FDA in 1987 for the treatment of adult acute myeloid leukemia and in 1996 for symptomatic hormone-refractory prostate cancer. In 2000… (More)


Cite this paper

@article{Fox2004MechanismOA, title={Mechanism of action of mitoxantrone.}, author={Edward J. Fox}, journal={Neurology}, year={2004}, volume={63 12 Suppl 6}, pages={S15-8} }